Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life (QOL) for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Transcript
What elements of cancer care are covered in your evaluation of cost effectiveness? Do you consider drug costs only or other costs, such as infusion time?
We've looked at, what are the potential savings? If we devise an algorithm, if we devise a framework saying, “Somebody is on LEN [lenalidomide] maintenance for a 2-year-period, they achieved 2 consecutive MRD negativity values, a 10T, separated by almost a year or so, are these the right patients to stop maintenance?” So, the answer is yes. What would be the cost savings is what we looked at.
We made some assumptions. If somebody stops with sustained MRD negativity, they should have more MRD testings that are incorporated into their care every 3 months, including a bone marrow biopsy, including the patient visiting every 3 months, and so on. Whereas the control patient population, what we normally do: these patients don't go through those repeat, sequential MRD testing to look for that MRD negativity. What we do in this patient population is to continue giving them the standard of care of LEN maintenance, until progression. Using these 2 frameworks—the framework that I described about the discontinuation of the treatment—and comparing the cost savings over time is what we looked at.
It is clearly showing that in the long run, there's a huge significant savings, both from the cost and from the quality-of-life perspective, and a significant savings advantage if you're able to find that right recipe to identify those patients who would be able to stop off maintenance, because continuing the treatment comes with its baggage. It comes with adverse events; it comes with the declining quality of life. Those all could be prevented by doing this.
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More